UK Markets closed

NFL Biosciences SA (ALNFL.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
3.2000+0.2000 (+6.67%)
At close: 04:37PM CET
Full screen
Previous close3.0000
Open2.9900
BidN/A x N/A
AskN/A x N/A
Day's range2.9900 - 3.2000
52-week range2.9200 - 5.0000
Volume3,757
Avg. volume11,644
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    NFL BIOSCIENCES: agreement signed with Diverchim to manufacture its active ingredients

    Montpellier, November 17, 2021 NFL Biosciences: agreement signed with Diverchim to manufacture its active ingredients Good manufacturing practices (GMP) production of the NFL-101 and NFL-201 active ingredients Long-term partnership to effectively manage and control manufacturing know-how NFL Biosciences SA, a biopharmaceutical company that is developing botanical drugs for the treatment of addictions, and Diverchim, a French market leader for the GMP development and production of novel molecules

  • Globe Newswire

    NFL Biosciences: Availability of the Half Year Financial Report as of June 30, 2021

    NFL Biosciences: Availability of the Half Year Financial Report as of June 30, 2021 NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL a biopharmaceutical company developing botanical drugs for the treatment of addictions, announced today, Monday, October 4, 2021, that it has made available to the public and filed with the Autorité des Marchés Financiers (AMF) its Half Year Financial Report for the period ended June 30, 2021. The Half-Year Financial Report can be consulted on the comp

  • Globe Newswire

    NFL BIOSCIENCES: 2021 half-year financial and business report

    NFL Biosciences: 2021 half-year financial and business report Admission on Euronext Growth Paris: €5m raised from institutional, historical, and individual investors (July 2021) CESTO II Phase II/III clinical trial approved in Australia (May 2021) and France (September 2021) Clinical team strengthened NFL Bioscience’s patent issued in the US (September 2021) “Innovative company” qualification by BPIfrance recognized NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceuti